Display Settings:

Format

Send to:

Choose Destination
Genes Cancer. 2013 Nov;4(11-12):476-85. doi: 10.1177/1947601913513268.

Akt signaling accelerates tumor recurrence following ras inhibition in the context of ink4a/arf loss.

Author information

  • 1Department of Surgery, University of Utah, Salt Lake City, UT, USA ; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
  • 2Georgetown University, Washington, DC, USA.

Abstract

Aberrant activation of the RAS signaling pathway contributes to nearly all human cancers, including gliomas. To determine the dependence of high-grade gliomas on this signaling pathway, we developed a doxycycline-regulated KRas glioma mouse model. Using this model we previously demonstrated that inhibition of KRas expression in gliomas induced by activated KRas and Akt results in complete tumor regression. We have also shown that, in the context of Ink4a/Arf loss, abrogation of KRas signaling is sufficient to decrease tumor burden but resistance ensues. In this study, we sought to determine the effect of activated Akt signaling in combination with activated KRas and loss of Ink4a/Arf on the growth and recurrence of brain tumors following suppression of KRas expression. We observed significant tumor formation in Ink4a/Arf(lox/lox) mice injected with retroviruses containing tetracycline responsive element (TRE)-KRas, Tet-off, Akt, and Cre. Abrogation of KRas signaling resulted in significant tumor regression; however, resistance developed after a relatively short latency. Tumor recurrence occurred more rapidly and the tumors were more aggressive in the presence of activated Akt signaling compared with loss of Ink4a/Arf alone suggesting that this pathway contributes to tumor progression in this context.

KEYWORDS:

Akt; Ink4a/Arf; Ras; glioma; mouse

PMID:
24386508
[PubMed]
PMCID:
PMC3877666
Free PMC Article

Images from this publication.See all images (5)Free text

Figure 1.
Figure 2.
Figure 3.
Figure 4.
Figure 5.
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk